Cartesian Therapeutics (RNAC) Stock Forecast, Price Target & Predictions
RNAC Stock Forecast
Cartesian Therapeutics stock forecast is as follows: an average price target of $44.00 (represents a 131.34% upside from RNAC’s last price of $19.02) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
RNAC Price Target
The average price target for Cartesian Therapeutics (RNAC) is $44.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $43.00. This represents a potential 131.34% upside from RNAC's last price of $19.02.
RNAC Analyst Ratings
According to 2 Wall Street analysts, Cartesian Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RNAC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cartesian Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Mitchell Kapoor | H.C. Wainwright | $45.00 | $12.87 | 249.65% | 136.59% |
| Jul 03, 2024 | John Newman | Canaccord Genuity | $43.00 | $15.77 | 172.67% | 126.08% |
| May 24, 2024 | Uy Ear | Mizuho Securities | $40.00 | $25.46 | 57.11% | 110.30% |
The latest Cartesian Therapeutics stock forecast, released on Aug 09, 2024 by Mitchell Kapoor from H.C. Wainwright, set a price target of $45.00, which represents a 249.65% increase from the stock price at the time of the forecast ($12.87), and a 136.59% increase from RNAC last price ($19.02).
Cartesian Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $42.67 |
| Last Closing Price | $19.02 | $19.02 | $19.02 |
| Upside/Downside | -100.00% | -100.00% | 124.34% |
In the current month, the average price target of Cartesian Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cartesian Therapeutics's last price of $19.02. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 06, 2024 | Cowen & Co. | Buy | Initialise | |
| Jul 02, 2024 | Oppenheimer | Outperform | Perform | Downgrade |
| Jun 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 04, 2024 | Oppenheimer | Outperform | Initialise |
Cartesian Therapeutics's last stock rating was published by H.C. Wainwright on Sep 04, 2024. The company gave RNAC a "Buy" rating, the same as its previous rate.
Cartesian Therapeutics Financial Forecast
Cartesian Therapeutics Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
Cartesian Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RNAC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Cartesian Therapeutics EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict RNAC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cartesian Therapeutics's previous annual EBITDA (undefined) of $NaN.
Cartesian Therapeutics Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Cartesian Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RNAC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Cartesian Therapeutics SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Cartesian Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to RNAC last annual SG&A of $NaN (undefined).
Cartesian Therapeutics EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, Cartesian Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RNAC previous annual EPS of $NaN (undefined).